No Data
No Data
Top Premarket Gainers
Express News | BioVie Inc - on Track to Receive Additional $12.6 Mln in Grant Funding From U.S. Department of Defense ("Dod") and Initiate Its Phase 2 Trial
Express News | BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long Covid
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
Express News | BioVie Inc -Patients Treated With Bezisterim Experienced 2 to 4 Years Age Deceleration Advantage Compared to Placebo
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting